Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye.
J Ocul Pharmacol Ther
October 2020
JeniVision, Inc., Irvine, California, USA.
JV-GL1 is an efficacious, potent, and long-acting antiglaucoma agent, according to studies in ocular normotensive and hypertensive monkeys. As an obligatory step in the drug development process, studies with exaggerated doses and an accelerated dosing schedule for JV-GL1 were performed in a second species (dog). Intraocular pressure (IOP) was measured by pneumatonometry in conscious Beagle dogs, which remained conscious throughout the study and gently restrained by hand.
View Article and Find Full Text PDFNew Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies.
Invest Ophthalmol Vis Sci
June 2018
MatTek Corporation, Ashland, Massachusetts, United States.
Purpose: The purpose of the current work was to develop a physiologically relevant, in vitro human three-dimensional (3D) corneal epithelial tissue model for use in ophthalmic drug development.
Methods: Normal human corneal epithelial cells were cultured at the air-liquid interface to produce the 3D corneal tissue model. Corneal barrier was determined by measuring transepithelial electrical resistance (TEER).
Latanoprost in the treatment of glaucoma.
Clin Ophthalmol
October 2014
Department of Neuroscience, Ophthalmology, University Hospital, Uppsala, Sweden.
Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α, which was the first of the currently available topical PGF2α analogs to be launched for glaucoma or ocular hypertension and which still accounts for the majority of prescriptions. It is better absorbed than the parent compound through the cornea, and peak concentration of the active drug is in the aqueous humor 1-2 hours after topical dosing (15-30 ng/mL).
View Article and Find Full Text PDFOcular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes.
Clin Ophthalmol
August 2013
InSite Vision, Alameda, CA, USA.
Purpose: To compare the aqueous humor (AH) and iris-ciliary body (ICB) concentration of bimatoprost in rabbit eyes treated with ISV-215 (0.03% bimatoprost formulated in DuraSite) with the marketed product bimatoprost 0.03% ophthalmic solution.
View Article and Find Full Text PDFComparison of human ocular distribution of bimatoprost and latanoprost.
J Ocul Pharmacol Ther
April 2012
Anne V. Goldberg Glaucoma Service, Willis Eye Institute, Philadelphia, PA, USA.
Purpose: This study investigated the ocular distribution of bimatoprost, latanoprost, and their acid hydrolysis products in the aqueous humor, cornea, sclera, iris, and ciliary body of patients treated with a single topical dose of 0.03% bimatoprost or 0.005% latanoprost for understanding concentration-activity relationships.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!